Swiss online pharmacy DocMorris 2025 revenue meets growth targets

DocMorris AG

20/01/2026 06:14

Overview

Swiss online pharmacy's 2025 external revenue grew 11.1%, achieving growth targets

2025 revenue increased by as much as 12.4% to CHF 1.12 billion, achieving growth targets

Digital services, including TeleClinic, saw significant growth in 2025

Q4 external revenue rose 15.5%, driven by increased marketing efficiency for prescription medicines

Outlook

DocMorris confirms EBITDA breakeven in 2026 and free cash flow breakeven in 2027

Company specifies 2025 EBITDA forecast to a range of minus CHF 48 to minus CHF 52 million

Result Drivers

DIGITAL SERVICES GROWTH - TeleClinic revenue increased by 124% in 2025, highlighting its strategic importance in the German market

AI ASSISTANT USAGE - Introduction of AI health assistant saw usage by every third app user, enhancing digital platform expansion

Q4 REVENUE ACCELERATION - Q4 external revenue rose 15.5%, driven by increased marketing efficiency for prescription medicines

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY External Revenue
CHF 1.19 bln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the drug retailers peer group is "buy."

Wall Street's median 12-month price target for DocMorris AG is CHF8.10, about 25.5% above its January 19 closing price of CHF6.46

Press Release: ID:nEQ2p2MfBa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)